You will be redirected to our submission process. Urothelial carcinoma (UC), which includes both bladder cancer and upper tract urothelial carcinoma (UTUC), remains one of the most aggressive and ...

The National Comprehensive Cancer Network recommends that all patients with stage IVA and stage IVB urothelial carcinoma have molecular analysis that integrates at least FGFR3 testing to help ...

"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says ...

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

Bladder cancers comprise heterogeneous cell populations, and numerous factors are likely to be involved in dictating recurrence, progression and patient survival. While several molecular markers ...

In this symposium chaired by Ravindran Kanesvaran, renowned experts Enrique Grande, Syed Hussain, and Ben Tran discuss the evolving therapeutic landscape in locally advanced/metastatic urothelial ...

Vetigenics, a clinical-stage animal health biotechnology company specializing in antibody therapeutics for pets, announces significant progress over the past year, including closing a $6 million seed ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will particip ...

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.